ClinicalTrials.gg
CompletedNCT04305197Updated Nov 30, 2022

A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)

A Phase 1/2 interventional study of ICP-022 and ICP-022 in Systemic Lupus Erythematosus, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Completed at 11 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-30.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Enrollment
89th of 245
60 · median 36
Started
2020
with 6 others
Phase 1/2
19 of 266
13 open now
Registered
41st of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 89th largest by enrollment of the 245 interventional ones that give a count, is one of 7 that started in 2020, is one of 19 in phase 1/2, and was the 41st registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

The purpose of the study is to assess the Safety, Tolerability, PK/PD and preliminary Efficacy of ICP-022 in Subjects with Systemic Lupus Erythematosus (SLE)

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Mild to Moderate
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged 18 to 75
  2. diagnosis of with SLE at least 6 months at screening visit
  3. SLEDAE-2K≥5
  4. Is receiving standard treatment for SLE and has been receiving treatment for at least 3 months.
  5. At least one SLE activity manifestation (as assessed by SLEDAE-2K)

Exclusion criteria

Exclusion Criteria:

  1. Failure to comply with the requirements of the programme
  2. A female or male partner who is pregnant or breastfeeding or who plans to become pregnant during the study period
  3. Previously treated with a BTK inhibitor
  4. Neuropsychiatric lupus (NPSLE)
  5. Has other diseases other than SLE

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Lower Dose

    Drug: ICP-022

  • Experimental
    Medium Dose

    Drug: ICP-022

  • Experimental
    Higher Dose

    Drug: ICP-022

  • Placebo comparator
    Placebo

    Drug: Placebos

Interventions

  • Tablet, 50mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period

    Also known as: Orelabrutinib

  • Tablet, 80mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period

    Also known as: Orelabrutinib

  • Tablet, 100mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period

    Also known as: Orelabrutinib

  • DrugPlacebos

    Tablet, matched to ICP-022, once a day, oral, will be administered for 12 weeks in double-blind treatment period

06

What researchers measure

Primary outcomes

  1. Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Up to 28 Days after the last dose of study drug

  2. Number of Patients with Treatment-emergent Adverse Event(TEAEs) according to severity

    Time frame: Up to 28 Days after the last dose of study drug

  3. Number of participants with clinically significant physical examination abnormalities

    Time frame: Up to 28 Days after the last dose of study drug

  4. Number of participants with clinically significant vital signs abnormalities

    Time frame: Up to 28 Days after the last dose of study drug

  5. Number of participants with clinically significant ECG abnormalities

    Time frame: Up to 28 Days after the last dose of study drug

  6. Number of participants with clinically significant laboratory examination abnormalities

    Time frame: Up to 28 Days after the last dose of study drug

Secondary outcomes

  1. Ratio of Patients With Response Based on Systemic Lupus Erythematosus Responder Index 4 (SRI-4)

    Time frame: 12 Weeks

  2. Ratio of Patients With Response Based on Systemic Lupus Erythematosus Responder Index 6 (SRI-6)

    Time frame: 12 Weeks

  3. Occupancy rate of Bruton Tyrosine Kinase(BTK)

    Time frame: 14 Days

  4. Serum Immunoglobulin (Ig) level

    Time frame: 12 Weeks

  5. Changes from Baseline in Ig levels

    Time frame: 12 Weeks

  6. Changes from Baseline in C3

    Time frame: 12 Weeks

  7. Changes from Baseline in C4

    Time frame: 12 Weeks

  8. Changes from Baseline in serum dsDNA

    Time frame: 12 Weeks

  9. Changes from Baseline in Anti-nuclear Antibodies

    Time frame: 12 Weeks

  10. Changes from Baseline in Interferon-α(INF-α) level

    Changes from Baseline in cytokine levels

    Time frame: 12 Weeks

  11. Changes from Baseline in Interleukin-6(IL-6) level

    Changes from Baseline in cytokine levels

    Time frame: 12 Weeks

  12. Changes from Baseline in total B cell counts

    Time frame: 12 Weeks

  13. Change from Baseline in Beffs count

    Time frame: 12 Weeks

  14. Changes from baseline in Bregs count

    Time frame: 12 Weeks

  15. Changes from Baseline in Bregs to Beffs ratio

    Time frame: 12 Weeks

  16. Changes from Baseline in Erythrocyte Sedimentation Rate(ESR)

    Time frame: 12 Weeks

  17. The plasma concentration-time curve

    Time frame: 14 Days

07

Study locations

11 sites
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui, China
  • Peking University People's Hospital
    Beijing, Beijing 100000, China
  • Peking University third hospital
    Beijing, Beijing 100000, China
  • Guangdong General Hospital
    Guangzhou, Guangdong, China
  • Shenzhen People's Hospital
    Shenzhen, Guangdong, China
  • University of Hong Kong Shenzhen Hospital
    Shenzhen, Guangdong, China
  • First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
  • Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • Gulou Hospital Affiliated to Medical College of Nanjing University
    Nanjing, Jiangsu 210000, China
  • Huashan Hospital affiliated to Fudan University
    Shanghai, Shanghai, China
  • The First Affiliated Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Apr 2022, 21 months.

Of 37 phase 1/2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2020
First posted
Mar 12, 2020
StartActual
Jul 9, 2020
Primary completionActual
Apr 28, 2022
CompletionActual
Apr 28, 2022
Last update
Nov 30, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04305197
Responsible party
Sponsor
First posted
Mar 12, 2020
Start date
Jul 9, 2020
Primary completion
Apr 28, 2022
Completion
Apr 28, 2022
Last update
Nov 30, 2022

Study contacts

Zhanguo Li, MD/PhD
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orelabrutinib

Start the discussion